Neurofascin as a novel target for autoantibody-mediated axonal injury

Journal of Experimental Medicine

Volumn 204, Issue 10, 2007, Pages 2363-2372

  Mathey, Emily K ^a   Derfuss, Tobias ^c,d   Storch, Maria K ^e   Williams, Kieran R ^a   Hales, Kimberly ^f   Woolley, David R ^b   Al Hayani, Abdulmonem ^b,g   Davies, Stephen N ^b   Rasband, Matthew N ^f   Olsson, Tomas ^h   Moldenhauer, Anja ⁱ   Velhin, Sviataslau ^c,j   Hohlfeld, Reinhard ^c,d   Meinl, Edgar ^c,d   Linington, Christopher ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^g KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j Research Institute for Epidemiology & Microbiology RIEM   (Belarus)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CELL ADHESION MOLECULE; GLYCOPROTEIN; IMMUNOGLOBULIN; ISOPROTEIN; MYELIN PROTEIN; NEUROFASCIN; NEUROFASCIN 155; NEUROFASCIN 186; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY REACTION; ARTICLE; AXONAL INJURY; BLOOD BRAIN BARRIER; BRAIN REGION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; MULTIPLE SCLEROSIS; MYELINATION; NEUROTRANSMISSION; NONHUMAN; OLIGODENDROGLIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PURIFICATION; PROTEOMICS; RAT; T LYMPHOCYTE; WESTERN BLOTTING;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; AXONS; CELL ADHESION MOLECULES; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; ELECTROPHYSIOLOGY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HELA CELLS; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE GROWTH FACTORS; RATS;

EID: 34948864286     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20071053     Document Type: Article

References (53)

1. Steinman, L. 2001. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2:762-764.
2. Hauser, S.L., and J.R. Oksenberg, 2006. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron, 52:61-76.
3. Trapp, B.D., R. Ransohoff, and R. Rudick, 1999. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12:295-302.
4. Ferguson, B., M.K. Matyszak, M.M. Esiri, and V.H. Perry, 1997. Axonal damage in acute multiple sclerosis lesions. Brain, 120:393-399.
5. Trapp, B.D., J. Peterson, R.M. Ransohoff, R. Rudick, S. Mork, and L. Bo, 1998. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338:278-285.
6. Redford, E.J., R. Kapoor, and K.J. Smith, 1997. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain, 120:2149-2157.
7. Wilkins, A., H. Majed, R. Layfield, A. Compston, and S. Chandran, 2003. Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor. J. Neurosci. 23:4967-4974.
8. Medana, I., Z. Li, A. Flügel, J. Tschopp, H. Wekerle, and H. Neumann, 2001. Fas ligand (CD95L) protects neurons against perforin-mediated T lymphocyte cytotoxicity. J. Immunol. 167:674-681.
9. Lily, O., J. Palace, and A. Vincent, 2004. Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain, 127:269-279.
10. Bjartmar, C., J.R. Wujek, and B.D. Trapp, 2003. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 206:165-171.
11. Lucchinetti, C., W. Brück, J. Parisi, B. Scheithauer, M. Rodriguez, and H. Lassmann, 2000. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47:707-717.
12. Genain, C.P., B. Cannella, S.L. Hauser, and C.S. Raine, 1999. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5:170-175.
13. Weinshenker, B.G., P.C. O ' Brien, T.M. Petterson, J.H. Noseworthy, C.F. Lucchinetti, D.W. Dodick, A.A. Pineda, L.N. Stevens, and M. Rodriguez, 1999. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Neurol. 46:878-886.
14. Keegan, M., F. Konig, R. McClelland, W. Bruck, Y. Morales, A. Bitsch, H. Panitch, H. Lassmann, B. Weinshenker, M. Rodriguez, et al, 2005. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet, 366:579-582.
15. Meinl, E., M. Krumbholz, and R. Hohlfeld, 2006. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann. Neurol. 59:880-892.
16. Linington, C., M. Bradl, H. Lassmann, C. Brunner, and K. Vass, 1988. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/ oligodendrocyte glycoprotein. Am. J. Pathol. 130:443-454.
17. Ozawa, K., T. Saida, K. Saida, H. Nishitani, and M. Kameyama, 1989. In vivo CNS demyelination mediated by anti-galactocerebroside antibody. Acta Neuropathol. (Berl.), 77:621-628.
18. Kanter, J.L., S. Narayana, P.P. Ho, I. Catz, K.G. Warren, R.A. Sobel, L. Steinman, and W.H. Robinson, 2006. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 12:138-143.
19. O ' Connor, K.C., K.A. McLaughlin, P.L. De Jager, T. Chitnis, E. Bettelli, C. Xu, W.H. Robinson, S.V. Cherry, A. Bar-Or, B. Banwell, et al, 2007. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat. Med. 13:211-217.
20. Zhou, D., R. Srivastava, S. Nessler, V. Grummel, N. Sommer, W. Bruck, H.P. Hartung, C. Stadelmann, and B. Hemmer, 2006. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc. Natl. Acad. Sci. USA, 103:19057-19062.
21. Ercolini, A.M., and S.D. Miller, 2006. Mechanisms of immunopathology in murine models of central nervous system demyelinating disease. J. Immunol. 176:3293-3298.
22. Sadatipour, B.T., J.M. Greer, and M.P. Pender, 1998. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann. Neurol. 44:980-983.
23. Eikelenboom, M.J., A. Petzold, R.H. Lazeron, E. Silber, M. Sharief, E.J. Thompson, F. Barkhof, G. Giovannoni, C.H. Polman, and B.M. Uitdehaag, 2003. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology, 60:219-223.
24. DeVries, G.H. 2004. Cryptic axonal antigens and axonal loss in multiple sclerosis. Neurochem. Res. 29:1999-2006.
25. Zhang, Y., R.R. Da, L.G. Hilgenberg, W.W. Tourtellotte, R.A. Sobel, M.A. Smith, M. Olek, R. Nagra, G. Sudhir, S. van den Noort, and Y. Qin, 2005. Clonal expansion of IgA-positive plasma cells and axon-reactive antibodies in MS lesions. J. Neuroimmunol. 167:120-130.
26. Sherman, D.L., S. Tait, S. Melrose, R. Johnson, B. Zonta, F.A. Court, W.B. Macklin, S. Meek, A.J. Smith, D.F. Cottrell, and P.J. Brophy, 2005. Neurofascins are required to establish axonal domains for saltatory conduction. Neuron, 48:737-742.
27. Ratcliffe, C.F., R.E. Westenbroek, R. Curtis, and W.A. Catterall, 2001. Sodium channel β1 and β3 subunits associate with neurofascin through their extracellular immunoglobulin-like domain. J. Cell Biol. 154:427-434.
28. Moldenhauer, A., J. Haas, C. Wascher, T. Derfuss, K.T. Hoffmann, H. Kiesewetter, and A. Salama, 2005. Immunoadsorption patients with multiple sclerosis: an open-label pilot study. Eur. J. Clin. Invest. 35:523-530.
29. Smith, K.J., and H. Lassmann, 2002. The role of nitric oxide in multiple sclerosis. Lancet Neurol. 1:232-241.
30. DeLuca, G.C., K. Williams, N. Evangelou, G.C. Ebers, and M.M. Esiri, 2006. The contribution of demyelination to axonal loss in multiple sclerosis. Brain, 129:1507-1516.
31. Parry, A., R. Corkill, A.M. Blamire, J. Palace, S. Narayanan, D. Arnold, P. Styles, and P.M. Matthews, 2003. Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J. Neurol. 250:171-178.
32. Coles, A.J., A. Cox, E. Le Page, J. Jones, S.A. Trip, J. Deans, S. Seaman, D.H. Miller, G. Hale, H. Waldmann, and D.A. Compston, 2006. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol. 253:98-108.
33. Davis, J.Q., S. Lambert, and V. Bennett, 1996. Molecular composition of the node of Ranvier: identification of ankyrin-binding cell adhesion molecules neurofascin (mucin+/third FNIII domain-) and NrCAM at nodal axon segments. J. Cell Biol. 135:1355-1367.
34. O'Hanlon, G.M., J.J. Plomp, M. Chakrabarti, I. Morrison, E.R. Wagner, C.S. Goodyear, X. Yin, B.D. Trapp, J. Conner, P.C. Molenaar, et al, 2001. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain, 124:893-906.
35. Nakano, S., and A.G. Engel, 1993. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology, 43:1167-1172.
36. Morgan, B.P., J.R. Dankert, and A.F. Esser, 1987. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J. Immunol. 138:246-253.
37. van Beek, J., M. van Meurs, B.A. ' t Hart, H.P. Brok, J.W. Neal, A. Chatagner, C.L. Harris, N. Omidvar, B.P. Morgan, J.D. Laman, and P. Gasque, 2005. Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation. J. Immunol. 174:2353-2365.
38. Arroyo, E.J., E.E. Sirkowski, R. Chitale, and S.S. Scherer, 2004. Acute demyelination disrupts the molecular organization of peripheral nervous system nodes. J. Comp. Neurol. 479:424-434.
39. Wolswijk, G., and R. Balesar, 2003. Changes in the expression and localization of the paranodal protein Caspr on axons in chronic multiple sclerosis. Brain, 126:1638-1649.
40. Howell, O.W., A. Palser, A. Polito, S. Melrose, B. Zonta, C. Scheiermann, A.J. Vora, P.J. Brophy, and R. Reynolds, 2006. Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis. Brain, 129:3173-3185.
41. Coman, I., M.S. Aigrot, D. Seilhean, R. Reynolds, J.A. Girault, B. Zalc, and C. Lubetzki, 2006. Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis. Brain, 129:3186-3195.
42. Charles, P., S. Tait, C. Faivre-Sarrailh, G. Barbin, F. Gunn-Moore, N. Denisenko-Nehrbass, A.M. Guennoc, J.A. Girault, P.J. Brophy, and C. Lubetzki, 2002. Neurofascin is a glial receptor for the paranodin/Caspr-contactin axonal complex at the axoglial junction. Curr. Biol. 12:217-220.
43. Azzi, G., J.F. Bernaudin, C. Bouchaud, B. Bellon, and J. Fleury-Feith, 1990. Permeability of the normal rat brain, spinal cord and dorsal root ganglia microcirculations to immunoglobulins G. Biol. Cell. 68:31-36.
44. Spies, J.M., K.W. Westland, J.G. Bonner, and J.D. Pollard, 1995. Intraneural activated T cells cause focal breakdown of the blood-nerve barrier. Brain, 118:857-868.
45. Kowal, C., L.A. DeGiorgio, T. Nakaoka, H. Hetherington, P.T. Huerta, B. Diamond, and B.T. Volpe, 2004. Cognition and immunity; antibody impairs memory. Immunity, 21:179-188.
46. Sospedra, M., and R. Martin, 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23:683-747.
47. Hochmeister, S., R. Grundtner, J. Bauer, B. Engelhardt, R. Lyck, G. Gordon, T. Korosec, A. Kutzelnigg, J.J. Berger, M. Bradl, et al, 2006. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J. Neuropathol. Exp. Neurol. 65:855-865.
48. Leech, S., J. Kirk, J. Plumb, and S. McQuaid, 2007. Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol. Appl. Neurobiol. 33:86-98.
49. Norton, W.T., and S.E. Poduslo, 1973. Myelination in rat brain: method of myelin isolation. J. Neurochem. 21:749-757.
50. Shevchenko, A., M. Wilm, O. Vorm, and M. Mann, 1996. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68:850-858.
51. Stefferl, A., A. Schubart, M. Storch, A. Amini, I. Mather, H. Lassmann, and C. Linington, 2000. Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. J. Immunol. 165:2859-2865.
52. Tait, S., F. Gunn-Moore, J.M. Collinson, J. Huang, C. Lubetzki, L. Pedraza, D.L. Sherman, D.R. Colman, and P.J. Brophy, 2000. An oligodendrocyte cell adhesion molecule at the site of assembly of the paranodal axo-glial junction. J. Cell Biol. 150:657-666.
53. Storch, M.K., A. Stefferl, U. Brehm, R. Weissert, E. Wallstrom, M. Kerschensteiner, T. Olsson, C. Linington, and H. Lassmann, 1998. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 8:681-694.